Drug intelligence / Profile preview

LBx-PA01

Development stage: Discontinued
Lead developer: Locus Biosciences
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

LBx-PA01 is an investigational CRISPR-Cas3–enhanced bacteriophage antimicrobial being developed by Locus Biosciences as a precision therapy targeting Pseudomonas aeruginosa, including multidrug-resistant strains that are a serious hospital-acquired infection threat. It consists of engineered bacteriophages programmed with guide RNAs to direct the Cas3 nuclease to P. aeruginosa DNA, causing extensive, irreversible genome degradation in addition to the natural lytic activity of the phages, thereby selectively killing the pathogen while sparing non-target bacteria.[5][6] The program was supported by a partnership with IDbyDNA to develop a metagenomic companion diagnostic (based on the Explify platform) to identify P. aeruginosa–infected patients most likely to benefit from LBx-PA01 in clinical trials.[5][6][10][13]

Targets

P. aeruginosa (Pseudomonas aeruginosa)

Beyond the preview

Go deeper on LBx-PA01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBx-PA01.

Explore the full profile